Not cheap but effective Preparations for resistant virus strains
For patients whose viruses are resistant to other active substances, further drugs from new substance classes have been approved: The first tablet attachment inhibitor fostemsavir - commercial name Rukobia - and the first monoclonal antibody: The entry inhibitor ibalizumab - trade name Trogarzo - is administered every two weeks as an infusion. It blocks the CD4 receptors on human T cells and thus prevents the pathogen from entering these cells.
"You now have a quite extensive range of antibodies that are extremely effective," says Kirchhoff. However, they have a very high price: The Institute for Quality and Efficiency in Health Care (IQWiG) put the annual costs for trogarzo therapy at about 120,000 euros in January.
https://www.welt.de/wissenschaft/article235285634/Zahl-der-AIDS-Toten-hat-sich-in-den-letzten-zehn-Jahren-halbiert.html